BioMarin Pharmaceutical Inc.
US ˙ NasdaqGS ˙ US09061G1013

SecurityBMRN / BioMarin Pharmaceutical Inc.
InstitutionCIBC Private Wealth Group, LLC
Latest Disclosed Ownership648 shares
Latest Disclosed Value $ 38,511
CIBC Private Wealth Group, LLC reports 38.17% increase in ownership of BMRN / BioMarin Pharmaceutical Inc.

On February 12, 2026 - CIBC Private Wealth Group, LLC filed a 13F-HR form disclosing ownership of 648 shares of BioMarin Pharmaceutical Inc. (US:BMRN) valued at $38,511 USD as of December 31, 2025. The entity filed a previous 13F-HR on November 24, 2025 disclosing 469 shares of BioMarin Pharmaceutical Inc.. This represents a change in shares of 38.17% during the quarter. The current value of the position is $35,420 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-02-12 2025-12-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 648 179 38.17 39 52.00 0.0001
2025-11-24 2025-09-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 469 147 45.65 25 47.06 0.0000
2025-08-12 2025-06-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 322 82 34.17 18 30.77 0.0000
2025-05-14 2025-03-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 240 -356 -59.73 13 -67.50 0.0000
2025-02-12 2024-12-31 13F BioMarin Pharmaceutical COM 09061G101 596 233 64.19 41 60.00 0.0001
2024-11-13 2024-09-30 13F BioMarin Pharmaceutical COM 09061G101 363 0 0.00 26 -16.67 0.0000
2024-08-09 2024-06-30 13F BioMarin Pharmaceutical COM 09061G101 363 -185 -33.76 30 -36.17 0.0001
2024-05-10 2024-03-31 13F BioMarin Pharmaceutical COM 09061G101 548 548 48 0.0001
2023-11-21 2023-03-31 13F/A-1 BIOMARIN PHARMACEUTICAL INC COM 09061G101 0 -9,453 -100.00 0 -100.00
2023-05-11 2023-03-31 13F BIOMARIN PHARMACEUTICAL INC COM COM 09061G101 0 -9,453 0
2023-06-01 2022-12-31 13F/A-2 BIOMARIN PHARMACEUTICAL INC COM 09061G101 9,453 -47,709 -83.46 549 -88.67 0.0018
2023-02-14 2022-12-31 13F/A-1 BIOMARIN PHARMACEUTICAL INC COM COM 09061G101 9,453 -47,709 978 0.0020
2023-02-13 2022-12-31 13F BIOMARIN PHARMACEUTICAL INC COM COM 09061G101 9,453 -47,709 978 0.0000
2022-11-15 2022-09-30 13F BIOMARIN PHARMACEUTICAL INC COM COM 09061G101 57,162 -5,113 -8.21 4,846 -6.09 0.0131
2022-08-03 2022-06-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 62,275 5 0.01 5,160 7.48 0.0134
2022-05-16 2022-03-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 62,270 0 0.00 4,801 -12.74 0.0105
2022-04-04 2021-12-31 13F/A-1 BIOMARIN PHARMACEUTICAL COM 09061G101 62,270 0 0.00 5,502 14.32 0.0114
2022-02-08 2021-12-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 62,270 0 5,502 0.0089
2021-11-12 2021-09-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 62,270 0 0.00 4,813 -7.37 0.0112
2021-08-16 2021-06-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 62,270 169 0.27 5,196 10.81 0.0119
2021-05-12 2021-03-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 62,101 -197 -0.32 4,689 -14.17 0.0118
2021-02-12 2020-12-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 62,298 17,798 40.00 5,463 61.34 0.0144
2020-11-03 2020-09-30 13F/A-1 BIOMARIN PHARMACEUTICAL COM 09061G101 44,500 44,500 3,386 0.0104
2020-08-13 2020-06-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 0 -28,460 -100.00 0 -100.00
2020-05-15 2020-03-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 28,460 100 0.35 2,405 0.29 0.0103
2020-01-30 2019-12-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 28,360 4,731 20.02 2,398 50.53 0.0078
2019-10-16 2019-09-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 23,629 19 0.08 1,593 -21.22 0.0056
2019-07-31 2019-06-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 23,610 39 0.17 2,022 -3.44 0.0071
2019-05-10 2019-03-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 23,571 756 3.31 2,094 7.77 0.0081
2019-02-05 2018-12-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 22,815 0 0.00 1,943 -12.16 0.0087
2018-11-14 2018-09-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 22,815 5 0.02 2,212 2.93 0.0084
2018-08-02 2018-06-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 22,810 1,470 6.89 2,149 24.22 0.0088
2018-05-17 2018-03-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 21,340 -6,533 -23.44 1,730 -30.38 0.0075
2018-02-12 2017-12-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 27,873 6,413 29.88 2,485 24.44 0.0105
2017-12-21 2017-09-30 13F/A-1 BIOMARIN PHARMACEUTL COM 09061G101 21,460 21,460 1,997 0.0091
2017-11-14 2017-09-30 13F BIOMARIN PHARMACEUTL COM 09061G101 21,460 1,997 0.0089
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.